Fact Check: Regeneron Pharmaceuticals initially announced it would purchase most of 23andMe’s assets for $256 million before Wojcicki's TTAM submitted a higher bid.

Fact Check: Regeneron Pharmaceuticals and 23andMe Asset Purchase

What We Know

The claim states that "Regeneron Pharmaceuticals initially announced it would purchase most of 23andMe’s assets for $256 million before Wojcicki's TTAM submitted a higher bid." This is supported by multiple sources. Regeneron Pharmaceuticals announced on May 19, 2025, that it would acquire most of 23andMe's assets for $256 million, which was reported by Reuters and CNBC. However, this acquisition was contested by Anne Wojcicki's nonprofit organization, TTAM Research Institute, which ultimately outbid Regeneron with a $305 million offer for 23andMe's assets, as confirmed by CNN and Globe Newswire.

Wojcicki, who is the co-founder and former CEO of 23andMe, stepped down from her position when the company filed for Chapter 11 bankruptcy in March 2025. The bidding war culminated in TTAM's successful bid, which was officially announced on June 13, 2025, and is pending approval from the U.S. Bankruptcy Court for the Eastern District of Missouri (CNBC, Globe Newswire).

Analysis

The evidence clearly indicates that Regeneron Pharmaceuticals did indeed announce an initial bid for 23andMe's assets at $256 million. This information is corroborated by reliable news outlets such as Reuters and CNBC, which are known for their journalistic integrity and fact-checking standards.

Furthermore, the subsequent bid by TTAM, led by Wojcicki, is also well-documented. The reports from CNN and Globe Newswire provide details about the final bid amount of $305 million and the context of the bidding process. Regeneron's decision not to increase its bid was based on its assessment of 23andMe's remaining value, as stated in their communication (CNN).

The sources used in this analysis are credible, with major news organizations and official press releases providing the information. There is no indication of bias in the reporting, as multiple outlets have covered the story consistently.

Conclusion

The claim that "Regeneron Pharmaceuticals initially announced it would purchase most of 23andMe’s assets for $256 million before Wojcicki's TTAM submitted a higher bid" is True. The timeline and details of the bids are well-supported by reliable sources, confirming the sequence of events leading to TTAM's successful acquisition of 23andMe.

Sources

1. 23andMe's founder Anne Wojcicki wins bid for bankrupt ...
2. Anne Wojcicki's nonprofit wins bid to acquire genetic ...
3. Anne Wojcicki to buy back 23andMe and its data for $305 ...
4. 23andMe Reaches Agreement for Sale of Business to TTAM ...
5. Anne Wojcicki Wins Bidding for 23andMe
6. Anne Wojcicki, the co-founder and former CEO of 23andMe ...
7. Former 23andMe CEO wins bidding war against Regeneron
8. Regeneron Enters into Asset Purchase Agreement to ...